Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 49Breast Neoplasms 47Neoplasms 39Leukemia, Lymphocytic, Chronic, B-Cell 37Carcinoma, Non-Small-Cell Lung 36Neoplasm Metastasis 29Lymphoma, Large B-Cell, Diffuse 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Brain Neoplasms 24Lymphoma, Follicular 23Lung Neoplasms 23Colonic Neoplasms 23Rectal Neoplasms 22Carcinoma, Renal Cell 22Lymphoma, Non-Hodgkin 21Prostatic Neoplasms 20Glioblastoma 20Leukemia, Myeloid, Acute 19Kidney Neoplasms 19Pancreatic Neoplasms 18Lymphoma, B-Cell, Marginal Zone 18Lymphoma, Mantle-Cell 17Gliosarcoma 17Burkitt Lymphoma 17Sarcoma 16Multiple Myeloma 16Waldenstrom Macroglobulinemia 15Ovarian Neoplasms 15Esophageal Neoplasms 15Lymphoma 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × NIH × Camurati-Engelmann Syndrome × Clear all
NCT04501094 2022-03-22

A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
2 enrolled 13 charts

Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡